厄贝沙坦联合阿托伐他汀对急性心肌梗死合并阵发性心房颤动患者复发的影响

目的 探讨厄贝沙坦联合阿托伐他汀对合并阵发性心房颤动(PAF)的急性心肌梗死(AMI)患者心房颤动复发的防治作用.方法 选择AMI合并PAF患者129例,按照随访期间药物应用情况分为联合组(67例)、阿托伐他汀组(21例)、厄贝沙坦组(23例)和对照组(18例).观察各组血压、血脂、左心房内径及血浆C反应蛋白水平的变化...

Effect of irbesartan combined with atorvastatin on relapse of paroxysmal atrial fibrillation in patients with acute myocardial infarction

Objective To evaluate the effect of irbesartan combined with atorvastatin on relapse of paroxysmal atrial fibrillation(PAF) in patients with acute myocardial infarction(AMI) complicated by PAF.Methods According to the drug used during follow-up,129 AMI patients with PAF were divided into groupⅠ(combined treatment group),groupⅡ(atorvastatin group),groupⅢ(irbesartan group) and groupⅣ(control group).Blood pressure,blood lipids,left atrial diameter and plasma C-reactive protein(CRP) level were recorded at the acute period and the end of the follow -up.Recurrence of PAF or conversion to persistent and permanent atrial fibrillation was observed. Results After treatment,SBP and left atrial diameter in groupsⅠandⅢwere significantly lower than those in groupsⅡandⅣ,while TC,TG,LDL-C,and CRP in groupⅠand groupⅡwere significantly lower than those in groupⅢand groupⅣ.Patients in groupⅠhad the lowest recurrence rate of PAF and the incidence rate of persistent or permanent atrial fibrillation during follow-up while those rates were lower in groupⅡand groupⅢthan in groupⅣ. Both atorvastatin and irbesartan were protective factors for preventing relapse of PAF in AMI patients. Conclusions Irbesartan combined with atorvastatin can effectively inhibit the relapse of PAF in patients with AMI.The mechanism is probably related to inhibiting inflammatory reaction, modulating serum lipids and improving atrial electric and structural remodeling.